Increased Coronary Atherosclerosis and Immune Activation in HIV-1 Elite Controllers

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2012 Oct 4

PMID 23032411

Citations 130

Authors

Florencia Pereyra

Janet Lo

Virginia A Triant

Jeffrey Wei

Maria J Buzon

Kathleen V Fitch

Janice Hwang

Jennifer H Campbell

Tricia H Burdo

Kenneth C Williams

Suhny Abbara

Steven K Grinspoon

Affiliations

Soon will be listed here.

Abstract

HIV-1 elite controllers spontaneously maintain suppressed levels of viremia, but exhibit significant immune activation. We investigated coronary atherosclerosis by coronary computed tomography angiography (CTA) in elite controllers, nonelite controller, chronically HIV-1 infected, antiretroviral therapy (ART)-treated patients with undetectable viral load ('chronic HIV'), and HIV-negative controls. Prevalence of atherosclerosis (78 vs. 42%, P < 0.05) and markers of immune activation were increased in elite controllers compared with HIV-negative controls. sCD163, a monocyte activation marker, was increased in elite controllers compared with chronic HIV-1 (P < 0.05) and compared with HIV-negative controls (P < 0.05). These data suggest a significant degree of coronary atherosclerosis and monocyte activation among elite controllers.

Citing Articles

Elucidating the role of KCTD10 in coronary atherosclerosis: Harnessing bioinformatics and machine learning to advance understanding.

Hu X, Liang F, Zheng M, Xie J, Wang S Sci Rep. 2025; 15(1):8168.

PMID: 40059128 PMC: 11891306. DOI: 10.1038/s41598-025-91376-3.

Comprehensive coronary CT angiography in people living with HIV: a systematic review and meta-analysis.

Phillips T, Blake G, Aun J, Conte L, Gadodia R, Tuli A BMJ Open. 2025; 15(2):e092264.

PMID: 39933814 PMC: 11815410. DOI: 10.1136/bmjopen-2024-092264.

Integrative bioinformatics and machine learning approach unveils potential biomarkers linking coronary atherosclerosis and fatty acid metabolism-associated gene.

Li H, Xu Y, Wang A, Zhao C, Zheng M, Xiang C J Cardiothorac Surg. 2025; 20(1):70.

PMID: 39825440 PMC: 11742484. DOI: 10.1186/s13019-024-03199-4.

HIV-1 controllers exhibit an enhanced antiretroviral innate state characterised by overexpression of p21 and MCPIP1 and silencing of ERVK-6 RNA expression.

de Azevedo S, Ribeiro-Alves M, Cortes F, Delatorre E, Hoagland B, Villela L Mem Inst Oswaldo Cruz. 2024; 119:e240071.

PMID: 39292108 PMC: 11404982. DOI: 10.1590/0074-02760240071.

Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission.

Bengu N, Cromhout G, Adland E, Govender K, Herbert N, Lim N Nat Med. 2024; 30(10):2796-2804.

PMID: 38843818 PMC: 11485204. DOI: 10.1038/s41591-024-03105-4.

References

Hunt P, Brenchley J, Sinclair E, McCune J, Roland M, Page-Shafer K . Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197(1):126-33. PMC: 3466592. DOI: 10.1086/524143. View

Pereyra F, Addo M, Kaufmann D, Liu Y, Miura T, Rathod A . Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008; 197(4):563-71. DOI: 10.1086/526786. View

Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho J . Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2009; 24(2):243-53. PMC: 3154841. DOI: 10.1097/QAD.0b013e328333ea9e. View

Burdo T, Lo J, Abbara S, Wei J, DeLelys M, Preffer F . Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011; 204(8):1227-36. PMC: 3203384. DOI: 10.1093/infdis/jir520. View

Buzon M, Seiss K, Weiss R, Brass A, Rosenberg E, Pereyra F . Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J Virol. 2011; 85(18):9646-50. PMC: 3165766. DOI: 10.1128/JVI.05327-11. View

Pereyra F, Jia X, McLaren P, de Bakker P, Walker B, Ripke S . The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010; 330(6010):1551-7. PMC: 3235490. DOI: 10.1126/science.1195271. View

Pereyra F, Palmer S, Miura T, Block B, Wiegand A, Rothchild A . Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009; 200(6):984-90. PMC: 3725728. DOI: 10.1086/605446. View

Hatano H, Delwart E, Norris P, Lee T, Dunn-Williams J, Hunt P . Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2008; 83(1):329-35. PMC: 2612329. DOI: 10.1128/JVI.01763-08. View

Hersperger A, Pereyra F, Nason M, Demers K, Sheth P, Shin L . Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010; 6(5):e1000917. PMC: 2877741. DOI: 10.1371/journal.ppat.1000917. View

10.

Buzon M, Massanella M, Llibre J, Esteve A, Dahl V, Puertas M . HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010; 16(4):460-5. DOI: 10.1038/nm.2111. View

11.

Kaplan R, Sinclair E, Landay A, Lurain N, Sharrett A, Gange S . T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011; 203(4):452-63. PMC: 3071219. DOI: 10.1093/infdis/jiq071. View

12.

Ridker P, Rifai N, Rose L, Buring J, Cook N . Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20):1557-65. DOI: 10.1056/NEJMoa021993. View

13.

Subramanian S, Tawakol A, Burdo T, Abbara S, Wei J, Vijayakumar J . Arterial inflammation in patients with HIV. JAMA. 2012; 308(4):379-86. PMC: 3724172. DOI: 10.1001/jama.2012.6698. View

14.

Migueles S, Osborne C, Royce C, Compton A, Joshi R, Weeks K . Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008; 29(6):1009-21. PMC: 2622434. DOI: 10.1016/j.immuni.2008.10.010. View

15.

Hsue P, Hunt P, Schnell A, Kalapus S, Hoh R, Ganz P . Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009; 23(9):1059-67. PMC: 2691772. DOI: 10.1097/QAD.0b013e32832b514b. View

16.

Deeks S, Walker B . Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007; 27(3):406-16. DOI: 10.1016/j.immuni.2007.08.010. View

17.

Torriani F, Komarow L, Parker R, Cotter B, Currier J, Dube M . Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008; 52(7):569-76. PMC: 2603599. DOI: 10.1016/j.jacc.2008.04.049. View

18.

Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L . HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005; 41(7):1053-6. DOI: 10.1086/433188. View

19.

OConnell K, Brennan T, Bailey J, Ray S, Siliciano R, Blankson J . Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol. 2010; 84(14):7018-28. PMC: 2898225. DOI: 10.1128/JVI.00548-10. View

20.

Boufassa F, Saez-Cirion A, Lechenadec J, Zucman D, Avettand-Fenoel V, Venet A . CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One. 2011; 6(4):e18726. PMC: 3080877. DOI: 10.1371/journal.pone.0018726. View